Cerebral glucose metabolic features of Parkinson disease and incident dementia: Longitudinal study

Journal of Nuclear Medicine

Volumn 52, Issue 6, 2011, Pages 848-855

  Bohnen, Nicolaas I ^a,b   Koeppe, Robert A ^a   Minoshima, Satoshi ^c   Giordani, Bruno ^d   Albin, Roger L ^a,b   Frey, Kirk A ^a,e   Kuhl, David E ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VAAAHS   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Dementia; Fluorodeoxyglucose; Lewy bodies; Occipital; Parkinson disease; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BRAIN METABOLISM; BRAIN REGION; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE DURATION; FEMALE; FRONTAL LOBE; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; LONGITUDINAL STUDY; MALE; OCCIPITAL CORTEX; PARIETAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; POSTERIOR CINGULATE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TEMPORAL LOBE; THALAMUS; VISUAL CORTEX;

ADULT; AGED; BRAIN CHEMISTRY; CEREBRAL CORTEX; COGNITION; COHORT STUDIES; DEMENTIA; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS;

EID: 79958141007     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.089946     Document Type: Article

References (33)

1. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci. 2010;289:18-22.
2. Mahler ME, Cummings JL. Alzheimer disease and the dementia of Parkinson disease: comparative investigations. Alzheimer Dis Assoc Disord. 1990;4:133-149. (Pubitemid 20292271)
3. Minoshima S, Foster NL, Kuhl DE. Posterior cingulate cortex in Alzheimer's disease. Lancet. 1994;344(8926):895. (Pubitemid 24290409)
4. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the e4 allele for Apolipoprotein E. N Engl J Med. 1996;334:752-758. (Pubitemid 26089356)
5. Vander Borght T, Minoshima S, Giordani B, et al. Cerebral metabolic differences in Parkinson's and Alzheimer's disease matched for dementia severity. J Nucl Med. 1997;38:797-802.
6. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-1872. (Pubitemid 43970103)
7. Hoehn M, Yahr M. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427-442.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-IIIR. 3rd, revised ed. Washington, DC: American Psychiatric Association; 1987.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944.
10. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
11. Lezak M. Neuropsychological Assessment. New York, NY: Oxford University Press; 1995.
12. Wechsler D. WAIS III Technical Manual. San Antonio, TX: The Psychological Corporation; 1997.
13. Wechsler D. Wechsler Memory Scale III Manual. San Antonio, TX: The Psychological Corporation; 1997.
14. Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. New York, NY: Thieme; 1988.
15. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med. 1994;35:1528-1537. (Pubitemid 24280464)
16. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238-1248.
17. Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer's disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 1995;19:541-547.
18. Kuhl DE, Metter J, Benson DF, et al. Similarities in cerebral glucose metabolism in Alzheimer's and Parkinsonian dementia. J Cereb Blood Flow Metab. 1985;5(suppl 1):S169-S170.
19. Kuhl D, Metter E, Riege W. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the [18F]fluorodeoxyglucose method. Ann Neurol. 1984;15:419-424. (Pubitemid 14145566)
20. 99mTc)-HMPAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer's type. J Neurol Neurosurg Psychiatry. 1991;54:787-792.
21. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging. 2003;30:1104-1113. (Pubitemid 36988222)
22. Bohnen NI, Minoshima S, Giordani B, Frey KA, Kuhl DE. Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia. Neurology. 1999;52:541-546. (Pubitemid 29075600)
23. Mosconi L, Mistur R, Switalski R, et al. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2009;36:811-822.
24. Boecker H, Ceballos-Baumann AO, Volk D, Conrad B, Forstl H, Haussermann P. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol. 2007;64:984-988. (Pubitemid 47047998)
25. Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol. 2004;61:1906-1911. (Pubitemid 39612951)
26. Foster ER, Campbell MC, Burack MA, et al. Amyloid imaging of Lewy body-associated disorders. Mov Disord. 2010;25:2516-2523.
27. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DE, Sima AAF. Fluorodeoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996;47:462-466. (Pubitemid 26324044)
28. Wolfson LI, Leenders KL, Brown LL, Jones T. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology. 1985;35:1399-1405. (Pubitemid 15242411)
29. Dahlstrom A, Fuxe K. Evidence for the existence of monoamine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand. 1964;62(suppl 232):1-55.
30. Perry RH, Tomlinson BE, Candy JM, et al. Cortical cholinergic deficit in mentally impaired Parkinsonian patients. Lancet. 1983;2:789-790.
31. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65:1716-1722.
32. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology. 2009;73:273-278.
33. Bussey T, Muir J, Everitt B, Robbins T. Dissociable effects of anterior and posterior cingulate cortex lesions on the acquisition of a conditional visual discrimination: facilitation of early learning vs. impairment of late learning. Behav Brain Res. 1996;82:45-56. (Pubitemid 27033625)